430 related articles for article (PubMed ID: 26198000)
1. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
4. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
7. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
10. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M
Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
[TBL] [Abstract][Full Text] [Related]
12.
Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
[TBL] [Abstract][Full Text] [Related]
13. Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.
Hatano T; Zhao S; Zhao Y; Nishijima K; Kuno N; Hanzawa H; Sakamoto T; Tamaki N; Kuge Y
Int J Oncol; 2013 Mar; 42(3):823-30. PubMed ID: 23338175
[TBL] [Abstract][Full Text] [Related]
14. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
Wyss MT; Honer M; Schubiger PA; Ametamey SM
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):311-8. PubMed ID: 16258762
[TBL] [Abstract][Full Text] [Related]
15. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Asaka T; Miyakoshi M; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2031-41. PubMed ID: 24867258
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
17. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
[TBL] [Abstract][Full Text] [Related]
19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
20. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
Dorow DS; Cullinane C; Conus N; Roselt P; Binns D; McCarthy TJ; McArthur GA; Hicks RJ
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):441-52. PubMed ID: 16450138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
